Short answer · Medically reviewed summary · Last updated: 2026-05-08
Agammaglobulinemia, most commonly X-linked agammaglobulinemia (XLA), is a rare primary immunodeficiency with an estimated prevalence of approximately 1 in 200,000 to 1 in 500,000 live births globally. While often considered an ultra-rare condition, the true prevalence of agammaglobulinemia is likely higher due to significant challenges in clinical recognition and underdiagnosis in many regions. What is the prevalence and incidence of agammaglobulinemia? The incidence of agammaglobulinemia is estimated at roughly 1 in 200,000 live births, though this varies by population.
What is the prevalence of Agammaglobulinemia?
Prevalence of Agammaglobulinemia: how many people are affected worldwide, differences by sex and region, with sources.
Agammaglobulinemia, most commonly X-linked agammaglobulinemia (XLA), is a rare primary immunodeficiency with an estimated prevalence of approximately 1 in 200,000 to 1 in 500,000 live births globally. While often considered an ultra-rare condition, the true prevalence of agammaglobulinemia is likely higher due to significant challenges in clinical recognition and underdiagnosis in many regions.
What is the prevalence and incidence of agammaglobulinemia?
The incidence of agammaglobulinemia is estimated at roughly 1 in 200,000 live births, though this varies by population. Because it is a rare disease, accurate global data is difficult to track. Many cases of agammaglobulinemia remain undiagnosed until adulthood, leading to discrepancies between birth incidence and actual prevalence in the general population.
Does agammaglobulinemia affect genders and ages differently?
The most common form, X-linked agammaglobulinemia, exclusively affects males because the defect is located on the X chromosome. While autosomal recessive forms exist, they are significantly rarer and affect both males and females equally. Regarding age, agammaglobulinemia is primarily identified in early childhood, typically after maternal antibodies wane (usually between 6 and 12 months of age), though delayed diagnosis in adults is a known clinical phenomenon.
Why is accurate data on agammaglobulinemia difficult to obtain?
- Underdiagnosis: Milder phenotypes or lack of immunological screening can delay detection for years.
- Misdiagnosis: Symptoms often overlap with common recurrent infections, leading to delayed referral to specialists.
- Geographic Variability: Diagnostic infrastructure varies significantly, causing lower reported numbers in developing regions.
- Community Insights: Data from the DiseaseMaps.org community, where 4 individuals currently share their experiences, highlights the diverse, individual journey of living with agammaglobulinemia.
Are there geographic or ethnic variations?
There is no specific evidence to suggest that agammaglobulinemia is more prevalent in any particular ethnic group; however, the autosomal recessive forms may appear more frequently in populations with higher rates of consanguinity.
Next steps
- Consult with a clinical immunologist for specialized testing, including serum immunoglobulin levels and B-cell count analysis.
- Connect with the agammaglobulinemia community at DiseaseMaps.org to share experiences and learn from others.
- Review resources from the Immune Deficiency Foundation (IDF) to better understand current management and treatment options like immunoglobulin replacement therapy.
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
References
- Orphanet: Rare Disease Database (ORPHA: 79361)
- NIH Genetic and Rare Diseases (GARD) Information Center
- OMIM: Online Mendelian Inheritance in Man (Entry #300300)
- Immune Deficiency Foundation (IDF) Patient Resources
